Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Identifieur interne : 000D06 ( Main/Corpus ); précédent : 000D05; suivant : 000D07Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
Auteurs : Durga Prasanna Misra ; Armen Yuri Gasparyan ; Olena ZimbaSource :
- Rheumatology international [ 1437-160X ] ; 2020.
English descriptors
- KwdEn :
- Antirheumatic Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Colchicine (adverse effects), Colchicine (therapeutic use), Coronavirus Infections (drug therapy), Drug Repositioning (MeSH), Hydroxychloroquine (adverse effects), Hydroxychloroquine (therapeutic use), Methotrexate (adverse effects), Methotrexate (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- chemical , adverse effects : Colchicine, Hydroxychloroquine, Methotrexate.
- chemical , therapeutic use : Antirheumatic Agents, Colchicine, Hydroxychloroquine, Methotrexate.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Drug Repositioning, Pandemics, SARS-CoV-2.
Abstract
Repurposing of antirheumatic drugs has garnered global attention. The aim of this article is to overview available evidence on the use of widely used antirheumatic drugs hydroxychloroquine, methotrexate and colchicine for additional indications. Hydroxychloroquine has endothelial stabilizing and anti-thrombotic effects. Its use has been explored as an adjunctive therapy in refractory thrombosis in antiphospholipid syndrome. It may also prevent recurrent pregnancy losses in the absence of antiphospholipid antibodies. Hydroxychloroquine favourably modulates atherogenic lipid and glycaemic profiles. Methotrexate has been tried for modulation of cardiovascular events in non-rheumatic clinical conditions, although a large clinical trial failed to demonstrate a benefit. Colchicine has been shown to successfully reduce the risk of recurrent cardiovascular events in a large multicentric trial. Potential antifibrotic effects of colchicine require further exploration. Hydroxychloroquine, methotrexate and colchicine are also being tried at different stages of the ongoing Coronavirus Disease 19 (COVID-19) pandemic for prophylaxis and treatment. While the use of these agents is being diversified, their adverse effects should be timely diagnosed and prevented. Hydroxychloroquine can cause retinopathy and rarely cardiac and auditory toxicity, retinopathy being dose and time dependent. Methotrexate can cause transaminitis, cytopenias and renal failure, particularly in acute overdoses. Colchicine can rarely cause myopathies, cardiomyopathy, cytopenias and transaminitis. Strong evidence is warranted to keep balance between benefits of repurposing these old antirheumatic drugs and risk of their adverse effects.
DOI: 10.1007/s00296-020-04694-2
PubMed: 32880032
PubMed Central: PMC7467139
Links to Exploration step
pubmed:32880032Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.</title><author><name sortKey="Misra, Durga Prasanna" sort="Misra, Durga Prasanna" uniqKey="Misra D" first="Durga Prasanna" last="Misra">Durga Prasanna Misra</name><affiliation><nlm:affiliation>Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Rae Bareli Road, Lucknow, 226014, India. durgapmisra@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Gasparyan, Armen Yuri" sort="Gasparyan, Armen Yuri" uniqKey="Gasparyan A" first="Armen Yuri" last="Gasparyan">Armen Yuri Gasparyan</name><affiliation><nlm:affiliation>Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zimba, Olena" sort="Zimba, Olena" uniqKey="Zimba O" first="Olena" last="Zimba">Olena Zimba</name><affiliation><nlm:affiliation>Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32880032</idno><idno type="pmid">32880032</idno><idno type="doi">10.1007/s00296-020-04694-2</idno><idno type="pmc">PMC7467139</idno><idno type="wicri:Area/Main/Corpus">000D06</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000D06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.</title><author><name sortKey="Misra, Durga Prasanna" sort="Misra, Durga Prasanna" uniqKey="Misra D" first="Durga Prasanna" last="Misra">Durga Prasanna Misra</name><affiliation><nlm:affiliation>Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Rae Bareli Road, Lucknow, 226014, India. durgapmisra@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Gasparyan, Armen Yuri" sort="Gasparyan, Armen Yuri" uniqKey="Gasparyan A" first="Armen Yuri" last="Gasparyan">Armen Yuri Gasparyan</name><affiliation><nlm:affiliation>Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Zimba, Olena" sort="Zimba, Olena" uniqKey="Zimba O" first="Olena" last="Zimba">Olena Zimba</name><affiliation><nlm:affiliation>Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Rheumatology international</title><idno type="eISSN">1437-160X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Colchicine (adverse effects)</term><term>Colchicine (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Drug Repositioning (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Methotrexate (adverse effects)</term><term>Methotrexate (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Colchicine</term><term>Hydroxychloroquine</term><term>Methotrexate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Colchicine</term><term>Hydroxychloroquine</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Drug Repositioning</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Repurposing of antirheumatic drugs has garnered global attention. The aim of this article is to overview available evidence on the use of widely used antirheumatic drugs hydroxychloroquine, methotrexate and colchicine for additional indications. Hydroxychloroquine has endothelial stabilizing and anti-thrombotic effects. Its use has been explored as an adjunctive therapy in refractory thrombosis in antiphospholipid syndrome. It may also prevent recurrent pregnancy losses in the absence of antiphospholipid antibodies. Hydroxychloroquine favourably modulates atherogenic lipid and glycaemic profiles. Methotrexate has been tried for modulation of cardiovascular events in non-rheumatic clinical conditions, although a large clinical trial failed to demonstrate a benefit. Colchicine has been shown to successfully reduce the risk of recurrent cardiovascular events in a large multicentric trial. Potential antifibrotic effects of colchicine require further exploration. Hydroxychloroquine, methotrexate and colchicine are also being tried at different stages of the ongoing Coronavirus Disease 19 (COVID-19) pandemic for prophylaxis and treatment. While the use of these agents is being diversified, their adverse effects should be timely diagnosed and prevented. Hydroxychloroquine can cause retinopathy and rarely cardiac and auditory toxicity, retinopathy being dose and time dependent. Methotrexate can cause transaminitis, cytopenias and renal failure, particularly in acute overdoses. Colchicine can rarely cause myopathies, cardiomyopathy, cytopenias and transaminitis. Strong evidence is warranted to keep balance between benefits of repurposing these old antirheumatic drugs and risk of their adverse effects.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32880032</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>11</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.</ArticleTitle><Pagination><MedlinePgn>1741-1751</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-020-04694-2</ELocationID><Abstract><AbstractText>Repurposing of antirheumatic drugs has garnered global attention. The aim of this article is to overview available evidence on the use of widely used antirheumatic drugs hydroxychloroquine, methotrexate and colchicine for additional indications. Hydroxychloroquine has endothelial stabilizing and anti-thrombotic effects. Its use has been explored as an adjunctive therapy in refractory thrombosis in antiphospholipid syndrome. It may also prevent recurrent pregnancy losses in the absence of antiphospholipid antibodies. Hydroxychloroquine favourably modulates atherogenic lipid and glycaemic profiles. Methotrexate has been tried for modulation of cardiovascular events in non-rheumatic clinical conditions, although a large clinical trial failed to demonstrate a benefit. Colchicine has been shown to successfully reduce the risk of recurrent cardiovascular events in a large multicentric trial. Potential antifibrotic effects of colchicine require further exploration. Hydroxychloroquine, methotrexate and colchicine are also being tried at different stages of the ongoing Coronavirus Disease 19 (COVID-19) pandemic for prophylaxis and treatment. While the use of these agents is being diversified, their adverse effects should be timely diagnosed and prevented. Hydroxychloroquine can cause retinopathy and rarely cardiac and auditory toxicity, retinopathy being dose and time dependent. Methotrexate can cause transaminitis, cytopenias and renal failure, particularly in acute overdoses. Colchicine can rarely cause myopathies, cardiomyopathy, cytopenias and transaminitis. Strong evidence is warranted to keep balance between benefits of repurposing these old antirheumatic drugs and risk of their adverse effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Misra</LastName><ForeName>Durga Prasanna</ForeName><Initials>DP</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5035-7396</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Rae Bareli Road, Lucknow, 226014, India. durgapmisra@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasparyan</LastName><ForeName>Armen Yuri</ForeName><Initials>AY</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-8749-6018</Identifier><AffiliationInfo><Affiliation>Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimba</LastName><ForeName>Olena</ForeName><Initials>O</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4188-8486</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>SML2Y3J35T</RegistryNumber><NameOfSubstance UI="D003078">Colchicine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Rheumatol Int. 2021 Mar;41(3):677-678</RefSource><PMID Version="1">33388902</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003078" MajorTopicYN="N">Colchicine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Cardiovascular risk</Keyword><Keyword MajorTopicYN="Y">Colchicine</Keyword><Keyword MajorTopicYN="Y">Fibrosis</Keyword><Keyword MajorTopicYN="Y">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">Methotrexate</Keyword><Keyword MajorTopicYN="Y">Thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>08</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32880032</ArticleId><ArticleId IdType="doi">10.1007/s00296-020-04694-2</ArticleId><ArticleId IdType="pii">10.1007/s00296-020-04694-2</ArticleId><ArticleId IdType="pmc">PMC7467139</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kingsmore KM, Grammer AC, Lipsky PE (2020) Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol 16:32–52. https://doi.org/10.1038/s41584-019-0337-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-019-0337-0</ArticleId><ArticleId IdType="pubmed">31831878</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerrigan SA, McInnes IB (2020) Reflections on 'older' drugs: learning new lessons in rheumatology. Nat Rev Rheumatol 16:179–183. https://doi.org/10.1038/s41584-020-0375-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0375-7</ArticleId><ArticleId IdType="pubmed">32066941</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39:2055–2062. https://doi.org/10.1007/s10067-020-05073-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05073-9</ArticleId><ArticleId IdType="pubmed">32277367</ArticleId></ArticleIdList></Reference><Reference><Citation>Suri JS, Puvvula A, Biswas M et al (2020) COVID-19 pathways for brain and heart injury in comorbidity patients: a role of medical imaging and artificial intelligence-based COVID severity classification: a review. Comput Biol Med 103960. https://doi.org/10.1016/j.compbiomed.2020.103960 .</Citation></Reference><Reference><Citation>Carfì A, Bernabei R, Landi F, for the Gemelli Against Covid-Post-Acute Care Study Group (2020) Persistent symptoms in patients after acute COVID-19. JAMA 324:603–605. https://doi.org/10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser E (2020) Long term respiratory complications of covid-19. BMJ 370:m3001. https://doi.org/10.1136/bmj.m3001</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3001</ArticleId><ArticleId IdType="pubmed">32747332</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrezenmeier E, Dorner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155–166. https://doi.org/10.1038/s41584-020-0372-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0372-x</ArticleId><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda S, Billoir P, Damian L et al (2019) Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. PLoS ONE 14:e0212614. https://doi.org/10.1371/journal.pone.0212614</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212614</ArticleId><ArticleId IdType="pubmed">30870459</ArticleId><ArticleId IdType="pmcid">6417644</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K, Breen K, Parmar K, Rand JH, Wu XX, Hunt BJ (2018) The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatology (Oxford) 57:120–124. https://doi.org/10.1093/rheumatology/kex378</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex378</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano S, Pierro L, Pantano I, Iudici M, Valentini G (2017) Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 44:1032–1038. https://doi.org/10.3899/jrheum.161351</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161351</ArticleId><ArticleId IdType="pubmed">28507183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CY, Lin YS, Su YJ et al (2017) Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. Rheumatology (Oxford) 56:2212–2221. https://doi.org/10.1093/rheumatology/kex357</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex357</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkan D, Unlu O, Sciascia S et al (2018) Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus 27:399–406. https://doi.org/10.1177/0961203317724219</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317724219</ArticleId><ArticleId IdType="pubmed">28764618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kravvariti E, Koutsogianni A, Samoli E, Sfikakis PP, Tektonidou MG (2020) The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. Autoimmun Rev 19:102491. https://doi.org/10.1016/j.autrev.2020.102491</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102491</ArticleId><ArticleId IdType="pubmed">32084592</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78:1296–1304. https://doi.org/10.1136/annrheumdis-2019-215213</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Belizna C, Pregnolato F, Abad S et al (2018) HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev 17:1153–1168. https://doi.org/10.1016/j.autrev.2018.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.05.012</ArticleId><ArticleId IdType="pubmed">30316994</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K, Breen K, Cohen H et al (2017) HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 43:562–571. https://doi.org/10.1055/s-0037-1603359</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1603359</ArticleId><ArticleId IdType="pubmed">28609801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekinian A, Vicaut E, Cohen J, Bornes M, Kayem G, Fain O (2018) Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL. Gynecol Obstet Fertil Senol 46:598–604. https://doi.org/10.1016/j.gofs.2018.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gofs.2018.06.008</ArticleId><ArticleId IdType="pubmed">30041771</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquier E, de Saint-Martin L, Marhic G et al (2019) Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study. BMJ Open 9:e025649. https://doi.org/10.1136/bmjopen-2018-025649</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-025649</ArticleId><ArticleId IdType="pubmed">30898821</ArticleId><ArticleId IdType="pmcid">6527997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Li G, Wang ZH, Wang LP, Dong PJ (2013) Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats. Exp Clin Cardiol 18:e95–98</Citation><ArticleIdList><ArticleId IdType="pubmed">23940455</ArticleId><ArticleId IdType="pmcid">3718607</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K (2017) Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis 76:848–854. https://doi.org/10.1136/annrheumdis-2016-209954</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209954</ArticleId><ArticleId IdType="pubmed">27836820</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HH, Chen DY, Lin CC, Chen YM, Lai KL, Lin CH (2017) Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. Ther Clin Risk Manag 13:583–592. https://doi.org/10.2147/tcrm.S130666</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/tcrm.S130666</ArticleId><ArticleId IdType="pubmed">28496328</ArticleId><ArticleId IdType="pmcid">5422572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillegraven S, Greenberg JD, Reed GW et al (2019) Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS ONE 14:e0210459. https://doi.org/10.1371/journal.pone.0210459</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0210459</ArticleId><ArticleId IdType="pubmed">30673733</ArticleId><ArticleId IdType="pmcid">6343881</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC (2019) Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjogren syndrome. QJM 112:757–762. https://doi.org/10.1093/qjmed/hcz112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcz112</ArticleId><ArticleId IdType="pubmed">31218368</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Hamid AAM, Firgany AEL (2016) Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. Acta Histochem 118:560–573. https://doi.org/10.1016/j.acthis.2016.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acthis.2016.06.002</ArticleId><ArticleId IdType="pubmed">27320898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia SH, Duran P, Lee ML, Davidson MB (2020) Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: a pilot study. J Diabetes 12:91–94. https://doi.org/10.1111/1753-0407.12989</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.12989</ArticleId><ArticleId IdType="pubmed">31574564</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikhbahaie F, Amini M, Gharipour M, Aminoroaya A, Taheri N (2016) The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. Adv Biomed Res 5:145. https://doi.org/10.4103/2277-9175.187401</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2277-9175.187401</ArticleId><ArticleId IdType="pubmed">27656614</ArticleId><ArticleId IdType="pmcid">5025914</ArticleId></ArticleIdList></Reference><Reference><Citation>Luthra A, Misra A (2015) The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol 3:758–760. https://doi.org/10.1016/s2213-8587(15)00328-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-8587(15)00328-9</ArticleId><ArticleId IdType="pubmed">26386988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Liu M, Li R et al (2016) Hydroxychloroquine, a promising choice for coronary artery disease? Med Hypotheses 93:5–7. https://doi.org/10.1016/j.mehy.2016.04.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2016.04.045</ArticleId><ArticleId IdType="pubmed">27372847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145–154. https://doi.org/10.1038/s41584-020-0373-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0373-9</ArticleId><ArticleId IdType="pubmed">32066940</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra DP, Shenoy SN (2017) Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int 37:151–167. https://doi.org/10.1007/s00296-016-3435-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-016-3435-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL (2015) Cardiovascular effects of methotrexate in rheumatoid arthritis revisited. Curr Med Chem 22:1903–1910. https://doi.org/10.2174/0929867322666150415122039</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867322666150415122039</ArticleId><ArticleId IdType="pubmed">25876749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouveia V, Oliveira DC, Tenorio E, Brito N, Sarinho E (2016) Percutaneous coronary intervention: safety of methotrexate and its possible benefits on restenosis after bare-metal stent deployment. Cardiol Res 7:104–109. https://doi.org/10.14740/cr468w</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/cr468w</ArticleId><ArticleId IdType="pubmed">28197276</ArticleId><ArticleId IdType="pmcid">5295516</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira DM, Lueneberg ME, da Silva RL, Fattah T, Gottschall CAM (2017) MethotrexaTE THerapy in ST-Segment Elevation MYocardial InfarctionS: a randomized double-blind, placebo-controlled trial (TETHYS Trial). J Cardiovasc Pharmacol Ther 22:538–545. https://doi.org/10.1177/1074248417699884</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248417699884</ArticleId><ArticleId IdType="pubmed">28325070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker PM, Everett BM, Pradhan A et al (2019) Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 380:752–762. https://doi.org/10.1056/NEJMoa1809798</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1809798</ArticleId><ArticleId IdType="pubmed">30415610</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11:1781–1794. https://doi.org/10.1517/17425255.2015.1076391</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425255.2015.1076391</ArticleId><ArticleId IdType="pubmed">26239119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat A, Naguwa SM, Cheema GS, Gershwin ME (2009) Colchicine revisited. Ann N Y Acad Sci 1173:766–773. https://doi.org/10.1111/j.1749-6632.2009.04674.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04674.x</ArticleId><ArticleId IdType="pubmed">19758227</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez GJ, Celermajer DS, Patel S (2018) The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis 269:262–271. https://doi.org/10.1016/j.atherosclerosis.2017.12.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2017.12.027</ArticleId><ArticleId IdType="pubmed">29352570</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisue K, Sugamura K, Kurokawa H et al (2017) Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. Circ J 81:1174–1182. https://doi.org/10.1253/circj.CJ-16-0949</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-16-0949</ArticleId><ArticleId IdType="pubmed">28420825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecconi A, Vilchez-Tschischke JP, Mateo J et al (2020) Effects of colchicine on atherosclerotic plaque stabilization: a multimodality imaging study in an animal model. J Cardiovasc Transl Res. https://doi.org/10.1007/s12265-020-09974-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12265-020-09974-7</ArticleId><ArticleId IdType="pubmed">32140929</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimmino G, Tarallo R, Conte S et al (2018) Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascul Pharmacol 111:62–70. https://doi.org/10.1016/j.vph.2018.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2018.09.004</ArticleId><ArticleId IdType="pubmed">30287213</ArticleId></ArticleIdList></Reference><Reference><Citation>Omma A, Sandikci SC, Kücüksahin O, Alisik M, Erel O (2017) Can the thiol/disulfide imbalance be a predictor of colchicine resistance in familial mediterranean fever? J Korean Med Sci 32:1588–1594. https://doi.org/10.3346/jkms.2017.32.10.1588</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2017.32.10.1588</ArticleId><ArticleId IdType="pubmed">28875601</ArticleId><ArticleId IdType="pmcid">5592171</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya K, Arnott C, Martinez GJ et al (2018) Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. JACC Cardiovasc Imaging 11:305–316. https://doi.org/10.1016/j.jcmg.2017.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2017.08.013</ArticleId><ArticleId IdType="pubmed">29055633</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajikawa M, Higashi Y, Tomiyama H et al (2019) Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. Int J Cardiol 281:35–39. https://doi.org/10.1016/j.ijcard.2019.01.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2019.01.054</ArticleId><ArticleId IdType="pubmed">30683457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker B, Kurup R, Barraclough J et al (2019) Colchicine as a novel therapy for suppressing chemokine production in patients with an acute coronary syndrome: a pilot study. Clin Ther 41:2172–2181. https://doi.org/10.1016/j.clinthera.2019.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2019.07.015</ArticleId><ArticleId IdType="pubmed">31409556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessy T, Soh L, Bowman M et al (2019) The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J 215:62–69. https://doi.org/10.1016/j.ahj.2019.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2019.06.003</ArticleId><ArticleId IdType="pubmed">31284074</ArticleId></ArticleIdList></Reference><Reference><Citation>Nidorf SM, Fiolet ATL, Eikelboom JW et al (2019) The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J 218:46–56. https://doi.org/10.1016/j.ahj.2019.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2019.09.011</ArticleId><ArticleId IdType="pubmed">31706144</ArticleId></ArticleIdList></Reference><Reference><Citation>Akodad M, Lattuca B, Nagot N et al (2017) COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch Cardiovasc Dis 110:395–402. https://doi.org/10.1016/j.acvd.2016.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2016.10.004</ArticleId><ArticleId IdType="pubmed">28065445</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardif JC, Kouz S, Waters DD et al (2019) Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 381:2497–2505. https://doi.org/10.1056/NEJMoa1912388</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912388</ArticleId><ArticleId IdType="pubmed">31733140</ArticleId></ArticleIdList></Reference><Reference><Citation>Masson W, Lobo M, Molinero G, Masson G, Lavalle-Cobo A (2020) Role of colchicine in stroke prevention: an updated meta-analysis. J Stroke Cerebrovasc Dis 104756. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104756</Citation></Reference><Reference><Citation>Deftereos SG, Vrachatis DA, Angelidis C et al (2019) The role of colchicine in treating postoperative and post-catheter ablation atrial fibrillation. Clin Ther 41:21–29. https://doi.org/10.1016/j.clinthera.2018.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2018.08.008</ArticleId><ArticleId IdType="pubmed">30217592</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue H, Liang W, Gu J et al (2019) Comparative transcriptome analysis to elucidate the therapeutic mechanism of colchicine against atrial fibrillation. Biomed Pharmacother 119:109422. https://doi.org/10.1016/j.biopha.2019.109422</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2019.109422</ArticleId><ArticleId IdType="pubmed">31514070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojaeifard M, Pakbaz M, Beheshti R et al (2020) The effect of colchicine on the echocardiographic constrictive physiology after coronary artery bypass graft surgery. Echocardiography 37:399–403. https://doi.org/10.1111/echo.14605</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/echo.14605</ArticleId><ArticleId IdType="pubmed">32175647</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan T, Gao B, Chen G et al (2013) Colchicine attenuates renal injury in a model of hypertensive chronic kidney disease. Am J Physiol Renal Physiol 305:F1466–1476. https://doi.org/10.1152/ajprenal.00057.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00057.2013</ArticleId><ArticleId IdType="pubmed">23946291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Jung ES, Lee J, Heo NJ, Na KY, Han JS (2018) Effects of colchicine on renal fibrosis and apoptosis in obstructed kidneys. Korean J Intern Med 33:568–576. https://doi.org/10.3904/kjim.2016.131</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2016.131</ArticleId><ArticleId IdType="pubmed">28298077</ArticleId></ArticleIdList></Reference><Reference><Citation>de Socio G, Verrecchia E, Fonnesu C, Giovinale M, Gasbarrini GB, Manna R (2010) Effectiveness of colchicine therapy in 4 cases of retroperitoneal fibrosis associated with autoinflammatory diseases. J Rheumatol 37:1971–1972. https://doi.org/10.3899/jrheum.100352</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100352</ArticleId><ArticleId IdType="pubmed">20810528</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigler A (2010) Use of colchicine to prevent recurrence of ear keloids. A new approach. J Plast Reconstr Aesthet Surg 63:e650–652. https://doi.org/10.1016/j.bjps.2010.03.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjps.2010.03.018</ArticleId><ArticleId IdType="pubmed">20347413</ArticleId></ArticleIdList></Reference><Reference><Citation>Daga D, Singh RK, Pal US, Gurung T, Gangwar S (2017) Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis. Natl J Maxillofac Surg 8:50–54. https://doi.org/10.4103/njms.NJMS_5_17</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/njms.NJMS_5_17</ArticleId><ArticleId IdType="pubmed">28761276</ArticleId><ArticleId IdType="pmcid">5512409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdemir O, Calisaneller T, Sonmez E, Kiyici H, Caner H, Altinors N (2010) Topical use of colchicine to prevent spinal epidural fibrosis in rats. Neurol Res 32:1117–1120. https://doi.org/10.1179/016164110x12681290831487</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/016164110x12681290831487</ArticleId><ArticleId IdType="pubmed">20444324</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntoni S, Rojkind M, Muntoni S (2010) Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease. World J Gastroenterol 16:2889–2894. https://doi.org/10.3748/wjg.v16.i23.2889</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i23.2889</ArticleId><ArticleId IdType="pubmed">20556834</ArticleId><ArticleId IdType="pmcid">2887584</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung J, Bonis PA, Kaplan MM (2011) Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 9:776–780. https://doi.org/10.1016/j.cgh.2011.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2011.05.010</ArticleId><ArticleId IdType="pubmed">21699802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaidis N, Polyzos SA, Giouleme O et al (2016) Colchicine to decrease inflammation and fibrosis in patients with metabolic dysregulation. Med Hypotheses 95:34. https://doi.org/10.1016/j.mehy.2016.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2016.08.006</ArticleId><ArticleId IdType="pubmed">27692162</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah S, Das S, Jain A, Misra DP, Negi VS (2020) A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis. https://doi.org/10.1111/1756-185x.13842</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185x.13842</ArticleId><ArticleId IdType="pubmed">32881350</ArticleId><ArticleId IdType="pmcid">7436606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn BY, Kang CK, Seo JD et al (2020) A case of breakthrough COVID-19 during hydroxychloroquine maintenance. J Korean Med Sci 35:e231. https://doi.org/10.3346/jkms.2020.35.e231</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e231</ArticleId><ArticleId IdType="pubmed">32567262</ArticleId><ArticleId IdType="pmcid">7308141</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattui SE, Liew JW, Graef ER et al (2020) Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev Clin Immunol. https://doi.org/10.1080/1744666x.2020.1792778</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666x.2020.1792778</ArticleId><ArticleId IdType="pubmed">32620062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurjar M, Agarwal V (2020) Usefulness of hydroxychloroquine for COVID-19: does answer lie in timing to start? Indian J Rheumatol (epub ahead of print)</Citation></Reference><Reference><Citation>Akpovwa H (2016) Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. Cell Biochem Funct 34:191–196. https://doi.org/10.1002/cbf.3182</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbf.3182</ArticleId><ArticleId IdType="pubmed">27001679</ArticleId><ArticleId IdType="pmcid">5071688</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Liang B, Aarthy M et al (2018) Hydroxychloroquine inhibits zika virus NS2B-NS3 protease. ACS Omega 3:18132–18141. https://doi.org/10.1021/acsomega.8b01002</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.8b01002</ArticleId><ArticleId IdType="pubmed">30613818</ArticleId><ArticleId IdType="pmcid">6312647</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra-Medina R, Sarmiento-Monroy JC, Rojas-Villarraga A, Garavito E, Montealegre-Gómez G, Gómez-López A (2020) Colchicine as a possible therapeutic option in COVID-19 infection. Clin Rheumatol 39:2485–2486. https://doi.org/10.1007/s10067-020-05247-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05247-5</ArticleId><ArticleId IdType="pubmed">32556936</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarsi M, Piantoni S, Colombo E et al (2020) Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217712</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217712</ArticleId><ArticleId IdType="pubmed">32855151</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslak F, Yildiz M, Adrovic A et al (2020) Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. Rheumatol Int 40:1423–1431. https://doi.org/10.1007/s00296-020-04645-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04645-x</ArticleId><ArticleId IdType="pubmed">32661928</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock D, Latz E, Morgan D, Brown R (2020) Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther 12:69. https://doi.org/10.1186/s13195-020-00640-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00640-3</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId><ArticleId IdType="pmcid">7271826</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi S, Reddy S, Gholamrezanezhad A (2020) Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect. J Thorac Imaging 35:W87–W89</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RTI.0000000000000534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Zimba O, Gasparyan AY (2020) Thrombosis in coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad. Clin Rheumatol 39:2529–2543. https://doi.org/10.1007/s10067-020-05275-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05275-1</ArticleId><ArticleId IdType="pubmed">32654082</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabias B, Kumar S (2016) Adverse neuropsychiatric effects of antimalarial drugs. Expert Opin Drug Saf 15:903–910. https://doi.org/10.1080/14740338.2016.1175428</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2016.1175428</ArticleId><ArticleId IdType="pubmed">27077782</ArticleId></ArticleIdList></Reference><Reference><Citation>Eo DR, Lee MG, Ham DI et al (2017) Frequency and clinical characteristics of hydroxychloroquine retinopathy in Korean patients with rheumatologic diseases. J Korean Med Sci 32:522–527. https://doi.org/10.3346/jkms.2017.32.3.522</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2017.32.3.522</ArticleId><ArticleId IdType="pubmed">28145658</ArticleId><ArticleId IdType="pmcid">5290114</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123:1386–1394. https://doi.org/10.1016/j.ophtha.2016.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId><ArticleId IdType="pubmed">26992838</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiehn C, Ness T, Weseloh C, et al. (2020) Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. Z Rheumatol. https://doi.org/10.1007/s00393-020-00785-4 (epub ahead of print)</Citation></Reference><Reference><Citation>Mason JW (2017) Antimicrobials and QT prolongation. J Antimicrob Chemother 72:1272–1274. https://doi.org/10.1093/jac/dkw591</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw591</ArticleId><ArticleId IdType="pubmed">28160473</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil A, Jerang Y, Mathew J (2020) Hydroxychloroquine-induced auditory toxicity. Indian J Rheumatol 15:53–55</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/injr.injr_130_19</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanos DP, Daniil Z, Zakynthinos E, Gourgoulianis K, Sakkas LI (2020) When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterr J Rheumatol 31:94–97. https://doi.org/10.31138/mjr.31.1.94</Citation><ArticleIdList><ArticleId IdType="doi">10.31138/mjr.31.1.94</ArticleId><ArticleId IdType="pubmed">32411941</ArticleId><ArticleId IdType="pmcid">7219635</ArticleId></ArticleIdList></Reference><Reference><Citation>Paliani U, Cardona A (2020) COVID-19 and hydroxychloroquine: is the wonder drug failing? Eur J Intern Med. https://doi.org/10.1016/j.ejim.2020.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.06.002</ArticleId><ArticleId IdType="pubmed">32709544</ArticleId><ArticleId IdType="pmcid">7269924</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21:1471–1482. https://doi.org/10.1634/theoncologist.2015-0164</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2015-0164</ArticleId><ArticleId IdType="pubmed">27496039</ArticleId><ArticleId IdType="pmcid">5153332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S (2020) Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int 40:765–770. https://doi.org/10.1007/s00296-020-04547-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04547-y</ArticleId><ArticleId IdType="pubmed">32170389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajmani S, Preet Singh Y, Prasad S et al (2017) Methotrexate-induced pancytopenia: a case series of 46 patients. Int J Rheum Dis 20:846–851. https://doi.org/10.1111/1756-185x.13004</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185x.13004</ArticleId><ArticleId IdType="pubmed">28261918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W-I, Hissaria P (2019) Drug-induced interstitial lung disease. Indian J Rheumatol 14:19–26. https://doi.org/10.4103/0973-3698.272161</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0973-3698.272161</ArticleId></ArticleIdList></Reference><Reference><Citation>Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH (2018) Update on colchicine, 2017. Rheumatology (Oxford) 57:i4–i11. https://doi.org/10.1093/rheumatology/kex453</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex453</ArticleId></ArticleIdList></Reference><Reference><Citation>Haj Yahia S, Ben Zvi I, Livneh A (2018) Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients. Rheumatol Int 38:141–147. https://doi.org/10.1007/s00296-017-3823-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-017-3823-1</ArticleId><ArticleId IdType="pubmed">28975396</ArticleId></ArticleIdList></Reference><Reference><Citation>Tal R, Semo Oz R, Amarilyo G et al (2020) Safety and efficacy of intravenous colchicine in children with familial Mediterranean fever. Rheumatol Int 40:121–128. https://doi.org/10.1007/s00296-019-04348-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04348-y</ArticleId><ArticleId IdType="pubmed">31230112</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman C, Farberov I, Feld O, Livneh A, Ben-Zvi I (2019) Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine. Rheumatol Int 39:517–523. https://doi.org/10.1007/s00296-018-04237-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-018-04237-w</ArticleId><ArticleId IdType="pubmed">30604205</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein Y, Aks SE, Hutson JR et al (2010) Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 48:407–414. https://doi.org/10.3109/15563650.2010.495348</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/15563650.2010.495348</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparyan AY, Ayvazyan L, Cocco G, Kitas GD (2012) Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 18:1543–1555. https://doi.org/10.2174/138161212799504759</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799504759</ArticleId><ArticleId IdType="pubmed">22364138</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti PM, Ewer KJ, Aley PK et al (2020) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(20)31604-4 .</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000D06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32880032
|texte= Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32880032" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |